SCHEMBL3677166

SCHEMBL3677166

C=CC1=C(c2ccc(O)cc2)C2CCCC2C1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 4/20 0.33
ESR1 P03372 2/20 0.33
MIF P14174 2/20 0.33
HPGD P15428 2/20 0.31
HSD17B10 Q99714 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
ALOX12 P18054 1/20 0.31
CASP1 P29466 1/20 0.31
RECQL P46063 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HTT P42858 1/20 0.31
KDM1A O60341 1/20 0.30
SENP1 Q9P0U3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3681309 0.82 HSD17B10 (0.32) ESR2ESR1MIFHPGDHSD17B10
SCHEMBL3681306 0.82 HSD17B10 (0.32) ESR2ESR1MIFHPGDHSD17B10
SCHEMBL3688807 0.82 HSD17B10 (0.32) ESR2ESR1MIFHPGDHSD17B10
SCHEMBL3683675 0.78 ESR2 (0.36) ESR2ESR1MIFGAAKDM1A
SCHEMBL3676121 0.78 ESR2 (0.36) ESR2ESR1MIFGAAKDM1A
SCHEMBL3684902 0.78 ESR2 (0.36) ESR2ESR1MIFGAAKDM1A
SCHEMBL3679284 0.76 ESR2 (0.38) ESR2ESR1MIFKDM1ASENP1
SCHEMBL3681589 0.76 ESR2 (0.35) ESR2ESR1MIFGAARAB9A
SCHEMBL3678586 0.75 ESR1 (0.33) ESR2ESR1HPGDHSD17B10KDM4E
SCHEMBL3640476 0.74 ESR2 (0.38) ESR2ESR1MIFRAB9AKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100210524-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-08-19 US claimed
EP-2176209-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-04-21 EP claimed
WO-2009012954-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-01-29 WO claimed
US-20100210524-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-08-19 US disclosed
EP-2176209-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-04-21 EP disclosed
WO-2009012954-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210524-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, ESR2 ESR2 3/4885ESR1 1/4885MIF 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.